WithdrawnPhase 2NCT02289144

Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer

Studying Anaplastic thyroid carcinoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Texas Southwestern Medical Center
Principal Investigator
Saad A Khan, MD
University of Texas Southwestern Medical Center
Intervention
Ceritinib(drug)
Eligibility
18 years · All sexes
Timeline
2015 – 2019

Study locations (1)

Collaborators

Novartis

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02289144 on ClinicalTrials.gov

Other trials for Anaplastic thyroid carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Anaplastic thyroid carcinoma →

← Back to all trials